CRISM Therapeutics (CRTX) Competitors GBX 8.21 -0.79 (-8.78%) As of 04:32 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitors CRTX vs. KAV, LND, CLA, GLR, PXC, BRES, ARV, TGR, PYX, and FRGShould you be buying CRISM Therapeutics stock or one of its competitors? The main competitors of CRISM Therapeutics include Kavango Resources (KAV), Landore Resources (LND), Celsius Resources (CLA), Galileo Resources (GLR), Phoenix Copper (PXC), Blencowe Resources (BRES), Artemis Resources (ARV), Tirupati Graphite (TGR), PYX Resources (PYX), and Firering Strategic Minerals (FRG). These companies are all part of the "other industrial metals & mining" industry. CRISM Therapeutics vs. Kavango Resources Landore Resources Celsius Resources Galileo Resources Phoenix Copper Blencowe Resources Artemis Resources Tirupati Graphite PYX Resources Firering Strategic Minerals Kavango Resources (LON:KAV) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking. Does the MarketBeat Community prefer KAV or CRTX? Kavango Resources and CRISM Therapeutics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformKavango ResourcesN/AN/ACRISM TherapeuticsN/AN/A Which has more volatility and risk, KAV or CRTX? Kavango Resources has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, CRISM Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Does the media refer more to KAV or CRTX? In the previous week, Kavango Resources' average media sentiment score of 0.00 equaled CRISM Therapeutics'average media sentiment score. Company Overall Sentiment Kavango Resources Neutral CRISM Therapeutics Neutral Is KAV or CRTX more profitable? Kavango Resources' return on equity of -20.89% beat CRISM Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kavango ResourcesN/A -20.89% -14.06% CRISM Therapeutics N/A -62.67%-26.77% Which has stronger valuation and earnings, KAV or CRTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKavango ResourcesN/AN/A-£3.60MN/AN/ACRISM TherapeuticsN/AN/A-£1.77M£8.221.05 SummaryCRISM Therapeutics beats Kavango Resources on 3 of the 5 factors compared between the two stocks. Get CRISM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRTX vs. The Competition Export to ExcelMetricCRISM TherapeuticsOther Industrial Metals & Mining IndustryMaterials SectorLON ExchangeMarket Cap£2.81M£896.86M£3.09B£2.04BDividend YieldN/A6.22%5.06%5.16%P/E Ratio1.0556.15109.751,926.65Price / SalesN/A50,549.85783,392.08384,006.48Price / CashN/A25.0924.1729.21Price / Book1.432.583.793.08Net Income-£1.77M£58.10M£152.86M£183.60M7 Day Performance-11.98%2.92%2.11%3.09%1 Month Performance-21.82%6.68%4.85%3.42%1 Year PerformanceN/A43.42%28.04%165.41% CRISM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRTXCRISM TherapeuticsN/AGBX 8.21-8.8%N/AN/A£2.68MN/A1.004Gap DownKAVKavango ResourcesN/AGBX 0.81-5.3%N/A+20.9%£12.56MN/A-3.1943Gap DownLNDLandore ResourcesN/AGBX 3.93+0.8%N/A+51.2%£12.29MN/A-393.006CLACelsius ResourcesN/AGBX 0.45-9.4%N/A-25.0%£11.64M£647.000.00N/AGap DownGLRGalileo ResourcesN/AGBX 0.92+6.4%N/A-16.3%£10.66MN/A-13.001Gap UpPXCPhoenix CopperN/AGBX 5+5.3%N/A-69.5%£9.23MN/A-500.0018Gap UpBRESBlencowe ResourcesN/AGBX 4.02-2.7%N/A-4.0%£9.09MN/A-401.503Gap UpARVArtemis ResourcesN/AGBX 0.45+5.2%N/A-54.4%£8.58MN/A-44.70N/AGap UpTGRTirupati GraphiteN/AGBX 6.25flatN/AN/A£8.09M£4.96M104.1736,000PYXPYX ResourcesN/AGBX 1.70-10.4%N/AN/A£7.85M£21.43M-325.0095Gap DownFRGFirering Strategic MineralsN/AGBX 4.20+2.4%N/A-25.8%£7.74M£1.61M-140.00N/A Related Companies and Tools Related Companies Kavango Resources Alternatives Landore Resources Alternatives Celsius Resources Alternatives Galileo Resources Alternatives Phoenix Copper Alternatives Blencowe Resources Alternatives Artemis Resources Alternatives Tirupati Graphite Alternatives PYX Resources Alternatives Firering Strategic Minerals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:CRTX) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISM Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRTX Stock Alerts